252
Views
19
CrossRef citations to date
0
Altmetric
Mutation Report

Vitreous amyloidosis in two large mainland Chinese kindreds resulting from transthyretin variant Lys35Thr and Leu55Arg

, , , , &
Pages 28-33 | Received 19 Feb 2011, Accepted 12 Jun 2011, Published online: 15 Aug 2011

REFERENCES

  • Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583–596.
  • Blevins G, Macaulay R, Harder S, Fladeland D, Yamashita T. Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His. Neurology 2003;60(10):1625–1630.
  • Araki S, Ikegawa S, Yi S, Murakami T, Ando Y, Miyazaki A, et al. Atypical cases of familial amyloidotic polyneuropathy (FAP) in Japan. In: Costa PP, Freitas AS, Saraiva MJM, eds. Familial Amyloidotic Polyneuropathy and Other Transthyretin Disorders. Porto: Arquivous de Medicina, 1990;267–270.
  • Haltia M, Prelli F, Kjuru S, Somer H, Palo J, Frangione B. Amyloid protein in familial amyloidosis (Finnish type) is homologous to gelsolin, an actin-binding protein. Biochem Biophys Res Commun 1990;167:927–931.
  • William CN, Richard EG, Bryan B Jr, Merrill DM. A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy. Genomics 1990;8:318–321.
  • Tawara S, Nakazato M, Kanagawa K, Matsuo H, Araki S. Identification of amyloid prealbumin variant in familial amyloidotic polyneuropathy (Japanese type). Biochem Biophys Res Commun 1983;116:880–888.
  • Dwulet FE, Benson MD. Characterization of transthyretin (prealbumin) variant associated with familial amyloidotic polyneuropathy type II (Indiana/Swiss). J Clin Invest 1986;78.
  • Benson MD, Uemichi T. Transthyretin amyloidosis. Amyloid Int Exp Clin Invest 1996;3:44–56.
  • Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003;10:160–184.
  • Lim A, Prokaeva T, Connor LH, Falk RH, Skinner M, Costello CE. Identification of a novel transthyretin Thr59Lys/Arg104His. A case of compound heterozygosity in a Chinese patient diagnosed with familial transthyretin amyloidosis. Amyloid 2002;9(2):134–40.
  • Lachmann HJ, Booth DR, Bybee A, Hawkins PN. Transthyretin Ala97Ser is associated with familial amyloidotic polyneuropathy in a Chinese–Taiwanese family. Hum Mutat 2000;16(2):180.
  • Mak CM, Lam CW, Fan ST, Liu CL, Tam SC. Genetics of familial amyloidotic polyneuropathy in a Hong Kong Chinese kindred. Acta Neurol Scand 2003;107(6):419–22.
  • Pica EC, Pramono ZA, Verma KK, San LP, Chee YW. A novel transthyretin mutation V32A in a Chinese man with late-onset amyloid polyneuropathy. Muscle Nerve 2005;32(2):223–225.
  • Chen L, Lü L, Zhang O. Transthyretin Arg-83 mutation in vitreous amyloidosis. Eye Science 2008;24(1):65–67.
  • Liu YT, Lee YC, Yang CC, Chen ML, Lin KP.Transthyretin Ala97Ser in Chinese-Taiwanese patients with familial amyloid polyneuropathy: genetic studies and phenotype expression. J Neurol Sci 2008 Apr 15;267(1–2):91–99.
  • Harats N, Worth RM, Benson MD. Hereditary amyloidosis: evidence against early amyloid deposition. Arthritis Rheum 1989;32:1474–1476.
  • Coelho T, Sousa A, Lourenco E, Ramalheira J. A study of 159 Portuguese patients with familial amyloidotic polyneuropathy (FAP) whose parents were both unaffected. J Med Genet 1994;31:293–299.
  • Sandgren O, Drugge U, Holmgren G, Sousa A. Vitreous involvement in familial amyloidotic neuropathy: a genealogical and genetic study. Clin Genet 1991;40:452–460.
  • Kyle RA, Gertz MA. Systemic amyloidosis. Crit Rev Oncol Hematol 1990;10:49–87.
  • Ando Y, Terazaki H, Nakamura M, Ando E, Haraoka K, Yamashita T, Ueda M, Okabe H, Sasaki Y, Tanihara H, Uchino M, Inomata Y. A different amyloid formation mechanism: de novo oculoleptomeningeal amyloid deposits after liver transplantation. Transplantation 2004 Feb 15; 77(3):345–349.
  • Munar-Qués M, Salvá-Ladaria L, Mulet-Perera P, Solé M, López-Andreu FR, Saraiva JM. Vitreous amyloidosis after liver transplantation in patients with familial amyloid polyneuropathy: ocular synthesis of mutant transthyretin. Amyloid Int J Exp Clin Invest 2000;7:266–269.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.